Telithromycin in lower respiratory tract infections

被引:5
作者
Blasi, F.
Cazzola, M.
Tarsia, P.
Aliberti, S.
Baldessari, C.
Valenti, V.
机构
[1] Univ Milan, Osped Maggiore, IRCCS, Inst Resp Dis, I-20122 Milan, Italy
[2] Carderelli Hosp, Dept Resp Med, Unit Pneumol & Allergol, Naples, Italy
关键词
acute exacerbations of chronic bronchitis; asthma; community-acquired pneumonia; telithromycin;
D O I
10.2217/17460913.1.1.7
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Telithromycin is a ketolide, a semisynthetic derivative of the 14-membered ring macrolide antibiotics, with an expanded spectrum of activity relative to macrolides. Its good tissue pharmacokinetic characteristics allows once-daily administration, and it has been successfully employed in lower respiratory tract infections. Recent data indicate that telithromycin may exert anti-inflammatory/immunomodulatory effects that may be of use in the treatment of both acute and chronic airway diseases. This review examines the role of telithromycin in lower respiratory tract infections, analyzing published data on exacerbations of chronic bronchitis, community-acquired pneumonia and asthma in adults. In addition, pharmacokinetic and pharmacodynamic properties of the drug are considered.
引用
收藏
页码:7 / 16
页数:10
相关论文
共 61 条
  • [31] Erythromycin inhibits beta(2)-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils
    Lin, HC
    Wang, CH
    Liu, CY
    Yu, CT
    Kuo, HP
    [J]. RESPIRATORY MEDICINE, 2000, 94 (07) : 654 - 660
  • [32] Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens
    Lodise, TP
    Preston, S
    Bhargava, V
    Bryskier, A
    Nusrat, R
    Chapel, S
    Rangaraju, M
    Drusano, GL
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 52 (01) : 45 - 52
  • [33] Telithromycin: A ketolide antibiotic for treatment of respiratory tract infections
    Lonks, JR
    Goldmann, DA
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) : 1657 - 1664
  • [34] Lorenz J, 2003, INT J CLIN PRACT, V57, P519
  • [35] ACUTE BRONCHIAL AND HEMATOLOGIC EFFECTS FOLLOWING INHALATION OF A SINGLE-DOSE OF PAF - COMPARISON BETWEEN ASTHMATICS AND NORMAL SUBJECTS
    LOUIS, R
    BURY, T
    CORHAY, JL
    RADERMECKER, MF
    [J]. CHEST, 1994, 106 (04) : 1094 - 1099
  • [36] Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections
    Low, DE
    Felmingham, D
    Brown, SD
    Rangaraju, M
    Nusrat, R
    [J]. JOURNAL OF INFECTION, 2004, 49 (02) : 115 - 125
  • [37] McGuire A, 2001, Value Health, V4, P370, DOI 10.1046/j.1524-4733.2001.45049.x
  • [38] Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647)
    Muller-Serieys, C
    Soler, P
    Cantalloube, C
    Lemaitre, F
    Gia, HP
    Brunner, F
    Andremont, A
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) : 3104 - 3108
  • [39] Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses
    Namour, F
    Wessels, DH
    Pascual, MH
    Reynolds, D
    Sultan, E
    Lenfant, B
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) : 170 - 175
  • [40] NICOLAU DP, 2003, CLIN MICROBIOL INFEC, V9, P397